The biggest risk from Donald Trump’s planned 100% tariff on imported generic drugs is not an immediate collapse in India’s pharmaceutical exports.
It is the possibility that one of the world’s largest generic-drug suppliers may have to rethink how it serves the US market. The tariff is not aimed specifically at India, but India’s deep position in generic medicines makes it particularly vulnerable.
With two years before the proposed levy takes effect, Indian drugmakers have time to respond, but the choices they make could reshape the industry’s global manufacturing footprint.
Two Years Before Tariff Shock
Under the plan reported by Reuters, imported generic drugs will remain exempt from the new tariff for two years from August 1, 2026. A 100% tariff is then scheduled to take effect from August 1, 2028, followed by a potential increase to 200% after another year.
That timeline matters. The policy is not an immediate trade shock for Indian pharmaceutical companies, but it creates a deadline for decisions that could take years to execute.
Pharmaceutical manufacturing depends on regulatory approvals, specialised facilities, quality systems and established supply chains. Building or expanding production in the US is therefore not comparable to shifting assembly of a conventional manufactured product.
For Indian companies, the next two years could become a period of strategic calculation. They may need to assess which medicines can continue to be exported competitively, which products could justify local US manufacturing and whether alternative markets can absorb volumes that become less economical to sell in America.
India Has Significant Exposure
India’s pharmaceutical industry has considerable global scale. Its pharmaceutical exports reached $30.47 billion in FY2024-25, an increase of 9.4% from the previous year. Generic pharmaceutical exports alone were valued at $24.15 billion during the year, according to Pharmexcil.
That does not mean the entire Indian pharmaceutical export industry is directly exposed to the proposed US tariff. The measure concerns imported generic drugs, and the eventual impact will depend on the precise scope and implementation of the policy.
But India’s importance in generic medicines makes the US market strategically significant. A tariff that effectively doubles the import cost of affected products could undermine the price advantage that makes overseas manufacturing commercially viable.
The potential impact is therefore likely to vary sharply between companies. Drugmakers with US manufacturing facilities or the financial capacity to expand their American footprint may have more options. Smaller exporters that depend heavily on shipping finished generic formulations from India could face greater pressure if the policy is implemented as announced.
America Has A Supply Chain Dilemma
The US, however, is not entering this debate from a position of complete manufacturing independence. The FDA says approximately nine out of every 10 prescriptions dispensed in the country are generic medicines. It also says more than half of pharmaceuticals distributed in the US are manufactured overseas.
That creates the central tension behind the tariff strategy.
Washington wants to encourage more pharmaceutical production inside the US and reduce dependence on foreign supply chains. But generic medicines are also a crucial part of keeping healthcare costs manageable. If domestic capacity does not expand quickly enough, imposing steep tariffs on imports could increase costs somewhere along the supply chain.
That does not necessarily mean patients will automatically pay more. Companies could absorb part of the cost, suppliers could renegotiate contracts, or manufacturers could shift production. But the possibility of higher costs or supply disruptions is a key consideration in any attempt to rapidly reshape the generic-drug supply chain.
India’s Manufacturing Advantage Tested
The issue extends beyond finished medicines. The FDA’s 2025 data on API manufacturing facilities showed that 9% were located in the US, compared with 44% in India and 22% in China. These figures describe the distribution of facilities in the FDA’s relevant dataset, rather than the countries’ shares of global API production.
The data nevertheless highlights why reshoring pharmaceuticals is complicated. Moving finished-drug production to the US does not automatically eliminate dependence on global supply chains. Pharmaceutical manufacturing involves multiple stages, from APIs and intermediates to formulation, packaging and distribution.
For Indian companies, this could encourage a more geographically diversified model. Instead of relying solely on exports from India, some manufacturers may consider greater US production, partnerships or acquisitions. Others may focus on markets where their cost advantage remains intact.
The result could be a gradual shift rather than a sudden exit from India.
A New Pharma Supply Chain
The proposed tariff therefore represents a broader test of the global generic-drug business model.
For India, the challenge is to protect its position as a low-cost manufacturing hub while deciding whether greater investment in the US is necessary to preserve access to its largest strategic markets. For American policymakers, the challenge is different but equally difficult: building domestic capacity without creating shortages or undermining the affordability of generic medicines.
The two-year exemption offers both sides time. For Indian drugmakers, it is a window to negotiate, diversify and invest. For the US, it is an opportunity to expand domestic capacity before tariffs potentially make imported generics significantly more expensive.
The most important question is therefore not whether India will lose its pharmaceutical industry to the US. There is no evidence to support such a conclusion.
The more realistic possibility is that the tariff could accelerate a rebalancing of pharmaceutical manufacturing, with Indian companies maintaining their manufacturing base at home while expanding their presence closer to the American market.
If that happens, Trump’s policy could achieve part of its intended goal, but at the cost of making the global generic-drug supply chain more complex and potentially more expensive.
The real test will be whether the US can build enough domestic capacity before the tariff deadline arrives, and whether Indian companies can adapt without sacrificing the cost advantage that made them global pharmaceutical leaders in the first place.
